Clinical Trial Update: Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of toripalimab combined with paclitaxel and cisplatin as neoadjuvant therapy for esophageal squamous cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• PACLITAXEL (PACLITAXEL)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking University | Conditions: Esophageal Squamous Cell Cancer | Phase 2 | Status: TERMINATED